NEW YORK (GenomeWeb News) – Procognia said today that GlaxoSmithKline will use its protein arrays to profile kinase kits in drug development research.
Under the agreement, GSK will use Procognia’s protein array technology with its own kinase inhibitors in profiling studies to assess whether it can integrate these arrays into its screening process.
GSK will have use of “over 300 functional kinases,” Procognia said. The Maidenhead, UK-based company said it hopes to “have a functional human protein array containing the entire human kinome” in the second quarter of this year.
Procognia also said its protein arrays are used for biomarker discovery, protein interaction, and in identifying substrates.
Financial terms of the agreement were not released.